Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights

Rationale: Effective cough treatments are a significant unmet need in patients with lung cancer. Aprepitant is a licensed treatment for nausea and vomiting, which blocks substance P activation of NK-1 (neurokinin 1) receptors, a mechanism also implicated in cough. Objectives: To assess aprepitant in...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Am J Respir Crit Care Med
Главные авторы: Smith, Jaclyn A., Harle, Amélie, Dockry, Rachel, Holt, Kimberley, Russell, Philip, Molassiotis, Alex, Yorke, Janelle, Robinson, Ryan, Birrell, Mark A., Belvisi, Maria G., Blackhall, Fiona
Формат: Artigo
Язык:Inglês
Опубликовано: American Thoracic Society 2021
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7958516/
https://ncbi.nlm.nih.gov/pubmed/32966755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1164/rccm.202006-2359OC
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы